ERBB2 and non-small cell lung carcinoma: As with HER2-amplified gastric cancers, where a cutoff of HER2:CEP17 ratio of >5 was defined for effective trastuzumab treatment [28], high-level MET amplification (MET/CEP7 >5) was found to give a positive clinical outcome based on the results from a study with crizotinib in non-small cell lung cancer [18].